G ender differences exist in nonalcoholic fatty liver disease (NAFLD) . Women are at a decreased risk of NAFLD compared with men at their reproductive age, whereas after menopause women lose the protective effect. [1] [2] [3] The risk of NAFLD in postmenopausal women appears diminished by the use of hormone replacement therapy (HRT). 4 The data suggest protective effects of female sex hormones against NAFLD. Among adult patients with nonalcoholic steatohepatitis (NASH), the risk of hepatic fibrosis differs on the basis of gender and menopausal state; premenopausal women have a decreased likelihood of hepatic fibrosis compared with men and postmenopausal women for a given grade of portal inflammation and hepatocyte ballooning. 5, 6 This suggests that at the same level of fibrogenic stimuli (ie, hepatocyte injury and inflammation), men and postmenopausal women are at a higher risk of hepatic fibrosis compared with premenopausal women.
How gender and menopause modulate host response to metabolic stress and influence the severity of hepatocyte injury and inflammation in NAFLD remain unknown. This is important because fibrogenesis is mainly driven by fibrogenic stimuli generated via hepatocyte injury and inflammation. 7, 8 Furthermore, most of current and future potential therapies target the reduction of metabolic stress, hepatocyte damage, and/or inflammation. Thus, better understanding of gender differences in such mechanisms is crucial to personalizing our therapeutic approach. We hypothesize that in adults, gender and different physiological sex hormone levels modulate hepatic injury and inflammation in response to metabolic stress in patients with NAFLD. In this study, we investigated the relationships of NASH histologic severity to gender, reproductive status, and hormone therapies at a given level of metabolic stress. We also assessed the associations of the histologic features to women-specific reproductive variances (menstrual abnormality, oral contraceptive use, and HRT) in premenopausal and postmenopausal women.
Methods

Study Design and Population
This is a hypothesis-driven, cross-sectional study. Data from the NASH Clinical Research Network (CRN) Database study, the Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-diabetic Patients with Nonalcoholic Steatohepatitis (PIVENS) trial at baseline, and NASH CRN Adult Database 2 project (before November 2013) were used. [9] [10] [11] Among adult patients (age !18 years) who had liver biopsy within 6 months of enrollment (N ¼ 1250), subjects not meeting histologic criteria for NAFLD (N ¼ 48) or reporting excess alcohol intake (!7 [women] or !14 [men] servings per week) (N ¼ 2) were excluded. Premenopausal women aged 45 or older (N ¼ 80), premenopausal women who reported estrogen-only product use (N ¼ 3), and postmenopausal women who reported progesterone-only product use (N ¼ 5) were removed from the analysis because of concerns over perimenopausal state or potential misclassification of menopausal state. The NASH CRN studies were approved by the Institutional Review Boards at all sites.
Liver Histology
All liver biopsy specimens were reviewed and scored by the NASH CRN Pathology Committee in a consensus manner according to the NASH CRN scoring system. 9 
Study Variables
Variables of menopausal state, menstrual patterns, and synthetic hormone use were created on the basis of self-reported information obtained via the study questionnaires. [9] [10] [11] The gender/menopause classification (men, premenopausal women, and postmenopausal women), menstrual patterns (none to rare vs others), oral contraceptive use, and HRT use were assessed for the associations with histologic grades of lobular inflammation, hepatocyte ballooning, portal inflammation, and Mallory-Denk bodies.
Covariates for the models were selected on the basis of key mechanistic concepts related to increased hepatic metabolic stress, increased free fatty acid delivery to the liver, and cellular senescence 12 : age (years), waist circumference (cm) standardized by body mass index (BMI) (kg/m 2 ), 12 the homeostatic model assessment of insulin resistance, 13 and steatosis grade. Demographic data, alcohol consumption (average servings per week), smoking history (current smokers vs others), selfreported diagnosis of polycystic ovary syndrome (PCOS), hypertension, and diabetes/impaired glucose tolerance were also collected at the study enrollment and considered in the analysis.
9-11
Statistical Analyses
Clinical and histologic characteristics of the study population were compared among the gender/menopause categories by using analysis of variance or Kruskal-Wallis test for continuous variables and c test for categorical variables. Histologic scores were compared by using Kruskal-Wallis tests with Wilcoxon rank-sum tests as post hoc pairwise comparisons.
Multiple logistic (or ordinal logistic) regression models were used to assess the associations between the gender/menopause categories and severity of NASH histologic features while adjusting for the abovementioned covariates, with and without including other potential confounding factors. The associations of menstrual abnormality, oral contraceptive use, and HRT to the histologic features were also assessed in premenopausal or postmenopausal women by using the same modeling approach. Significance of the associations was determined by using likelihood ratio tests. Adjusted odds ratios or cumulative odds ratios (ACORs) with 95% confidence interval (CI) were computed by using the models.
All the statistical analyses were performed by using JMP statistical software v.9.0 (SAS Institute, Cary, NC).
Results
Patient Characteristics
Men, premenopausal women, and postmenopausal women comprised 42%, 14%, and 44% of the study population, respectively (N ¼ 1112). Clinical characteristics and histologic features of NAFLD are summarized for the gender/menopause categories in Table 1 .
Associations of Gender, Reproductive Status, and Synthetic Hormones With Nonalcoholic Steatohepatitis Histologic Features
The associations of gender and menopause with NASH histologic features are summarized in Table 2 . Compared with premenopausal women, men had a decreased risk of having severe lobular inflammation, hepatocyte ballooning, and Mallory-Denk bodies, whereas postmenopausal women had a decreased risk of having severe lobular inflammation and Mallory-Denk bodies (Model 1, Table 2 ). The results remained consistent even after adjusting for other potential clinical confounders (Model 2, Table 2 ). NOTE. In pairwise comparisons of histologic features, grades of steatosis and lobular inflammation were higher in premenopausal women compared with men (P < .01) and postmenopausal women (P < .01). Grade of hepatocyte ballooning and presence of Mallory-Denk bodies were lower in men compared with premenopausal (P < .01) and postmenopausal (P < .01) women. Stage of liver fibrosis and grade of portal inflammation were highest in postmenopausal women, followed by men and premenopausal women (P < .01).
a Median (interquartile range). b Self-reported alcohol consumption <7 servings per week (women) and <14 servings per week (men).
Oral contraceptive use in premenopausal women was associated with increased likelihood of having more severe lobular inflammation and Mallory-Denk bodies (Supplementary Table 1 , Model 1). HRT in postmenopausal women was associated with increased risk of having severe lobular inflammation (Supplementary  Table 2 , Models 1 and 2).
PCOS was not associated with NASH histologic features in both univariate/multivariate analyses, and association between oral contraceptive and NASH histologic features was not altered after adjusting for PCOS (data not shown).
Discussion
Our analysis showed that premenopausal women have a higher grade of lobular inflammation, hepatocyte ballooning, and Mallory-Denk bodies compared with men at a given level of metabolic stress. In the subanalyses of women only, oral contraceptive use was associated with increased risk of having more severe lobular inflammation and Mallory-Denk bodies among premenopausal women. In postmenopausal women, HRT was associated with increased risk of having more severe lobular inflammation.
The above findings suggest that gender, menopause, and synthetic hormone use may modulate degree of hepatocyte injury and inflammation in response to metabolic stress and influence the intensity of fibrogenic stimuli that drive fibrogenesis. Histologic grades of lobular inflammation and Mallory-Denk bodies were higher in premenopausal women vs men and postmenopausal women, suggesting hormonal effects. This is counterintuitive because most of the data from animal models show "protective" effects of estrogens on liver injury, regardless of injury stimuli. 14, 15 In our extended analysis in which variables of progesterone use and estrogen use were separately incorporated in the model, progesterone use, but not estrogen use, was associated with more severe lobular inflammation and MalloryDenk bodies (data not shown). This suggests the detrimental impact may be explained by a higher level of progesterone, but not estrogen. Further investigation on how gender and sex hormone levels differentially influence NAFLD pathobiology, cellular stress response, and cell death is warranted.
It is noteworthy that despite their enhanced hepatocyte injury and inflammation, premenopausal women were associated with lower stage of hepatic fibrosis compared with postmenopausal women and men. Furthermore, consistent with previous studies, 5, 6 premenopausal women were at decreased risk of hepatic fibrosis compared with men and postmenopausal women at a given level of hepatocyte ballooning and portal inflammation in this independent population (data not shown). Thus, impacts of gender/sex hormones on NASH features appear to be multifaceted. Use of oral contraceptive in women who have multiple NAFLD risk factors could be detrimental, especially in women who have a condition of estrogen depletion. Further validation studies are required to develop robust clinical recommendations.
This study has several limitations including potential referral bias (patients were enrolled at tertiary academic centers), recall bias (self-reported menopausal category and synthetic hormone use), the lack of information on cumulative estrogen and/or progesterone exposure (eg, pregnancies, duration of synthetic hormone use), and possible underdiagnosis of PCOS. Because of the crosssectional nature, duration of exposure to an increased metabolic stress in the liver was not taken into account in the analysis. Last, we did not measure serum estrogen/progesterone levels or their signaling pathway activation. Therefore, whether the observed associations can be explained by hormonal effects versus innate sex differences cannot be confirmed. Nonetheless, our analysis provides hypotheses pertaining to gender differences and multifaceted impact of sex hormones in NAFLD, which can be tested in future multidisciplinary investigations.
In conclusion, our hypothesis-driven analysis demonstrated distinct associations of gender, menopause, oral contraceptive use, and HRT with hepatic lobular inflammation/injury, providing an interesting theory pertaining to complex effects of sex and sex hormones on human NAFLD. Gender differences in NASH clinical phenotypes and pathophysiology should be further characterized in future studies to develop a personalized approach to patients with NAFLD. 
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